Freya Meds Review: What Its GLP-1 Documents Establish—and What They Do Not

A medication name is not an evidence package. Freya Meds markets an online weight-management program offering potential prescriptions for semaglutide or tirzepatide, ongoing clinical contact and home delivery. Those features describe what the company proposes to arrange; they do not establish which preparation a patient will receive or what results Freya patients achieve. For someone evaluating the service, the central task is connecting the advertised program to an identifiable product, accountable clinician and understandable payment agreement.

This review examines public documentation consulted October 19, 2026. Freya provides useful detail about assessments, support and advertised prices, while its legal terms clarify that independent clinicians—not Freya itself—make treatment decisions. The documents also contain meaningful inconsistencies: homepage prices differ from treatment-page prices, and a 50-state marketing claim sits alongside explicit state exclusions. The strongest reading preserves those differences rather than selecting whichever version makes the service appear simpler.

At a glance

Clinical responsibility: Freya describes itself as a nonclinical administrative and technology platform. The patient-provider relationship is with an independent clinician practicing through an affiliated professional entity.
Sources: [8]
Two sets of advertised prices: The homepage lists semaglutide starting as low as $150 per month and tirzepatide starting as low as $249. Treatment pages list $250 and $332 per month with quarterly billing and delivery, or $297 and $390 for monthly plans.
Sources: [5] [9] [10]
Availability conflict: The homepage advertises patients across all 50 states, but the terms exclude Alabama, Mississippi and West Virginia and restrict services to people located in the United States.
Sources: [5] [8]
Product identification remains incomplete: The terms contemplate compounded medications and acknowledge their lack of FDA approval. The consulted documentation does not establish the exact formulation, route or presentation of every product dispensed.
Sources: [8] [5]
Cash-pay service: Freya and its affiliated entities say they do not accept commercial insurance or participate in Medicare or Medicaid. The terms make users responsible for associated clinician, laboratory and pharmacy charges.
Sources: [8]

Start with the product, not the ingredient name

Freya’s homepage describes a fully online program connecting patients with licensed doctors who can prescribe semaglutide or tirzepatide. Its terms also expressly contemplate compounded medications prepared by licensed pharmacies for individual patients. These statements establish the program’s advertised scope, but not a complete product specification. The consulted documentation does not settle the formulation, presentation, administration route or compounded status of each product a patient might actually receive. References to syringes or vials do not resolve those questions.

That distinction matters when evaluating Freya’s comparisons with familiar branded medicines. References to Ozempic, Wegovy, Mounjaro or Zepbound do not establish that those brands are supplied, that a preparation is FDA approved, or that evidence transfers unchanged. FDA approval concerns a specific product, not a clinic or pharmacy. Our guide to approved medicines and compounded preparations explains why identifying the actual prescription is a separate step from recognizing its advertised ingredient.

Freya’s terms acknowledge that compounded preparations are not FDA reviewed or approved for safety, efficacy or manufacturing quality, and disclaim guarantees concerning their safety, efficacy, purity or quality. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. It does mean that the company’s marketing cannot substitute for product-specific documentation.

Sources: [5] [8] [1]

What clinical research can—and cannot—say about Freya

Clinical research on semaglutide and tirzepatide is not research on Freya’s delivery model. STEP 1 studied a specified subcutaneous semaglutide regimen in adults without diabetes over 68 weeks; SURMOUNT-1 studied specified subcutaneous tirzepatide regimens in adults without diabetes over 72 weeks. Neither trial was a test of Freya, its clinicians or an unidentified compounded preparation. Their findings cannot establish this provider’s results, the performance of another route or an individual patient’s likely outcome.

Freya’s homepage advertises more than 450,000 patients across 50 states and uses a headline about losing up to 100 pounds. These are provider marketing claims, not independently verified outcome findings in this review. Patient volume, even if documented, would not by itself establish average weight change, tolerability or persistence with treatment. The consulted materials do not provide a provider-specific outcomes study that connects those claims to a defined population, product, follow-up period and accounting for patients who stopped.

The practical evidence question is therefore narrower than whether these medication ingredients have been researched. It is whether the treatment offered to a particular patient corresponds to the product and circumstances behind an evidence claim. Our explanation of why a clinical trial is not a company performance report provides that framework. Freya’s documents support describing an advertised care service; they do not support ranking its clinical effectiveness against another provider.

Sources: [5] [3] [4]

Who evaluates the patient and owns the clinical decision?

Freya’s legal structure is more specific than its consumer-facing description. The terms identify FREYA MEDS International Inc. and affiliates as the operator, while the document’s heading uses FREYA MEDS INC. They describe Freya as a nonclinical administrative and technology management service for independent, state-licensed professional corporations. Freya says it does not practice medicine or employ or contract with healthcare providers to deliver clinical services. The consulted documentation does not resolve the naming differences or identify the affiliated clinical corporations.

The terms place diagnosis, treatment and prescribing with the independent licensed clinician practicing through an affiliated entity. Enrollment begins with an advertised confidential assessment about health, goals and lifestyle, described as requiring no commitment. A clinician reviews medical history, current medications, weight goals and the overall medical profile; Freya explicitly says not everyone qualifies. Its same-day review claim is an advertised review timetable, not a guarantee of a prescription or of medication arrival.

The service is intended for adults 18 and older. The semaglutide page describes a BMI of 27 or above as a preferred profile, but that marketing description is not a complete eligibility policy. Nor should it replace the clinician’s assessment. Before enrollment, a useful request is the responsible clinician’s name, professional credential and affiliated practice, together with an explanation of how the assessment is conducted. This review did not independently verify professional licenses.

Sources: [8] [6] [5] [9]

The price evidence does not produce one clear quote

Freya publishes actual prices, but they do not form a single reconciled offer. The homepage’s starting amounts are lower than the monthly equivalents displayed on treatment pages. The latter distinguish quarterly billing and delivery from monthly plans. A quarterly option is not the only payment structure shown, and its advertised duration does not establish a particular vial count or minimum commitment. None of these listings fully identifies the formulation, route and presentation attached to the price.

The homepage also advertises up to $272 off three-month plans at checkout, ending October 31 without specifying a year. That is insufficient to confirm current availability or explain the lower starting prices. Freya says payment covers the complete monthly treatment plan rather than a specific vial, with cost unchanged by the clinician’s individual dose determination. That statement should not be expanded into a permanent price guarantee or used to fill gaps in the checkout agreement.

Published price statements, not an individualized quote
Advertised option	Published amount and interval	Important boundary
Homepage semaglutide	Starting as low as $150 per month	Conditions for obtaining the minimum are not explained.
Homepage tirzepatide	Starting as low as $249 per month	Relationship to treatment-page prices is unresolved.
Treatment-page semaglutide	$250 per month, billed and delivered quarterly; $297 per month for monthly plans	Monthly and quarterly structures are both advertised.
Treatment-page tirzepatide	$332 per month, billed and delivered quarterly; $390 per month for monthly plans	Exact product formulation, route and presentation remain unspecified.
Three-month promotion	Up to $272 off at checkout; ends October 31	No year is given; current applicability is unconfirmed.

Sources: [5] [9] [10]

Included care, separate charges and cancellation boundaries

The homepage says pricing usually includes medication, syringes, shipping and access to consultations and support. “Usually” is a material qualification. Treatment-page benefits include medication, unlimited doctor consultations, monthly group calls and a one-on-one dietitian consultation. Other advertised resources include nutrition plans, meal guidance, habit-building tools and dashboard progress tracking. These are meaningful service descriptions, but the documentation does not establish session duration, scheduling availability or how frequently every resource can be used.

The legal terms say users are responsible for all associated fees, including clinician, laboratory and pharmacy services, with payments handled by third-party processors. They also describe a cash-pay arrangement: Freya and affiliated entities do not accept commercial insurance and do not participate in Medicare or Medicaid. Required laboratory testing and whether any such costs are included remain unclear. The broad responsibility clause makes an itemized checkout explanation more useful than relying solely on “no hidden fees” advertising.

Freya advertises no membership fees, no lock-in, month-to-month care and cancellation at any time. Those statements coexist with quarterly billing and delivery. The consulted documentation does not explain automatic renewal rules, a cancellation deadline or procedure, refunds of quarterly prepayments, or payment treatment if a prescription is declined. Cancellation language alone does not establish a refund right. A prospective patient should obtain those operational terms before selecting either billing interval.

Sources: [5] [9] [6] [8]

Geography, pharmacy choice and delivery need separate checks

The clearest geographic boundary appears in the terms: services are for people located in the United States, and residents of Alabama, Mississippi and West Virginia cannot purchase services. That directly qualifies the homepage’s claim of patients across all 50 states. It would be misleading to turn the latter into verified current nationwide availability. Eligibility to complete checkout in a particular location should be confirmed against the service’s current terms, not assumed from the marketing headline.

If a prescription is issued, the terms allow selection of a partner pharmacy to ship it. A patient-selected pharmacy is also contemplated, but only when that option is presented during use of the service. The consulted materials do not name the dispensing pharmacies. They also disclose that medications fulfilled through Freya’s pharmacy network will not arrive in child-resistant packaging. That is a concrete handling limitation, separate from any claim about discreet or free shipping.

Freya advertises free, discreet shipping and a “Fast 3 Day Shipping” service, while quarterly plans specify quarterly delivery. The three-day phrase does not identify when the clock starts or whether it refers to dispatch, transit or arrival. Claims of proper storage do not document packaging or the cold chain. For an injectable GLP-1 product arriving warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. Our delivery-evidence guide separates logistics claims from demonstrated handling.

Sources: [8] [5] [9] [10] [1]

Follow-up is advertised more clearly than response standards

Freya advertises continuity with the same doctor, weekly check-ins and treatment adjustments, plus messaging access to the practitioner who knows the case. The homepage promises unlimited clinician and care-team access and monthly expert sessions with questions and answers. Together, these features describe a program intended to continue beyond the initial prescription. What they do not establish is a guaranteed response time, the format of each weekly contact or availability outside published administrative hours.

For problems during treatment, the semaglutide page directs patients to contact their practitioner, who can reconsider the approach based on their response. This is a documented clinical contact path, not evidence that every concern receives immediate attention. The terms expressly exclude emergency care and direct people experiencing a medical emergency to call 911 and seek immediate treatment. The public documentation also does not confirm Spanish-language care, interpretation or disability accommodations.

NIDDK describes follow-up as attention to treatment response and tolerability, not simply continued payment. Freya’s advertised check-ins are therefore relevant, but their practical quality cannot be established from a feature list. Before paying, ask who reviews messages, how urgent concerns are routed and what happens if the usual practitioner is unavailable. Our guide to clinical follow-up beyond renewals explains the distinction without assuming that an advertised access benefit guarantees a particular clinical experience.

Sources: [9] [5] [6] [8] [2]

Build a written record before making a payment

Freya’s privacy policy supplies contact@freyameds.com, a mailing address at 30 N Gould St Ste R, Sheridan, WY 82801, and hours of 8 a.m. to 8 p.m. Eastern, Monday through Sunday. Those published hours should not be treated as a clinician-response guarantee. The policy also permits requests for data access, correction or deletion and objections to certain processing, subject to applicable law. These are documented administrative channels rather than proof of how quickly requests will be resolved.

The terms provide a separate record-transfer route: patients can email doctor@freyameds.com with consent and the receiving clinician’s name, address and telephone number. That is useful for coordinating care outside the platform. The terms also describe individual binding arbitration in English, with exceptions in the document; this does not establish the language of clinical care. Together, these provisions show why reading beyond treatment pages matters when evaluating responsibilities and access.

The most useful prepayment record would identify the prescribing practice, clinician and pharmacy; specify the actual product; and reconcile the selected price with billing, delivery and cancellation terms. It should also explain possible laboratory charges, handling of a declined prescription and delivery-problem procedures. These requests address gaps in the consulted documentation rather than proving the service lacks those processes. Written answers would make the advertised program substantially easier to evaluate.

Sources: [7] [8] [5] [9] [10]

Questions & answers

Does Freya guarantee that I will receive a prescription?

No. Freya says a licensed clinician reviews health history, medications, goals and the overall medical profile, and not everyone qualifies. Its same-day review claim does not guarantee prescribing. The consulted documentation also does not explain how payment is handled when a prescription is declined, so that is worth clarifying before checkout.

Sources: [5] [8]

What should I expect to pay for Freya semaglutide?

The homepage advertises a starting price as low as $150 per month, without explaining the qualifying conditions. The semaglutide page instead lists $250 per month with quarterly billing and delivery, or $297 per month for monthly plans. These are different published offers, not one confirmed quote. Ask which product, services and billing terms accompany the selected price.

Sources: [5] [9]

Can I use Freya from Alabama, Mississippi or West Virginia?

The consulted terms explicitly say services are unavailable to residents of those three states and that they cannot complete checkout. This conflicts with the broad impression created by the homepage’s 50-state patient claim. The service is also intended only for people located in the United States. Do not treat the homepage headline as confirmation of current local availability.

Sources: [8] [5]

Does Freya identify the pharmacy or guarantee my preferred pharmacy?

The terms describe a partner-pharmacy network but the consulted documents do not name the dispensing pharmacies. They allow use of a pharmacy chosen by the patient when that option is presented during the service. That qualification matters: the documents do not establish unrestricted pharmacy choice at every stage. Ask which pharmacy would dispense your particular prescription before payment.

Sources: [8]

Does “cancel anytime” mean a quarterly payment is refundable?

Not on the documentation reviewed. Freya advertises cancellation at any time and no lock-in, but also offers quarterly billing and delivery. The consulted materials do not explain refunds of prepaid amounts, cancellation procedures or renewal deadlines. Ending future service and recovering money already paid are separate questions; request written answers for the selected plan.

Sources: [9] [10] [5]

How can I contact Freya or transfer my telehealth record?

The privacy policy lists contact@freyameds.com and daily administrative hours of 8 a.m. to 8 p.m. Eastern. For a record transfer, the terms direct patients to doctor@freyameds.com with consent and the receiving provider’s name, address and phone number. Neither channel establishes an immediate clinical response, and Freya expressly does not provide emergency care.

Sources: [7] [8]

Our assessment

Freya documents a recognizable cash-pay telehealth model, with clinician assessment, advertised ongoing contact, nutritional resources and pharmacy delivery. Its terms usefully distinguish administrative services from independent clinical responsibility and disclose important compounded-medication limitations. The evidence is less complete where a purchase becomes specific: exact product identity, responsible practices and pharmacies, reconciled pricing, renewal and refund rules, and delivery handling. Clinical trials of medication products do not close those gaps or verify Freya’s promotional outcomes. The balanced conclusion is neither an endorsement nor a finding that the service is ineffective: Freya describes substantial offerings, but a prospective patient still needs written, individualized service and product details to evaluate what is actually being purchased.

Visit Freya / Freya Meds’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Freya Meds Review: What Its GLP-1 Documents Establish—and What They Do Not

At a glance

01Start with the product, not the ingredient name

02What clinical research can—and cannot—say about Freya

03Who evaluates the patient and owns the clinical decision?

04The price evidence does not produce one clear quote

05Included care, separate charges and cancellation boundaries

06Geography, pharmacy choice and delivery need separate checks

07Follow-up is advertised more clearly than response standards

08Build a written record before making a payment